Articles - 4zim mentioned but not cited (3)
- An inhibitor of cholesterol absorption displays anti-myeloma activity by targeting the JAK2-STAT3 signaling pathway. Xu X, Han K, Zhu J, Mao H, Lin X, Zhang Z, Cao B, Zeng Y, Mao X. Oncotarget 7 75539-75550 (2016)
- Discovery of Novel Antiangiogenic Marine Natural Product Scaffolds. Ebrahim HY, El Sayed KA. Mar Drugs 14 (2016)
- Prediction of Ordered Water Molecules in Protein Binding Sites from Molecular Dynamics Simulations: The Impact of Ligand Binding on Hydration Networks. Rudling A, Orro A, Carlsson J. J Chem Inf Model 58 350-361 (2018)
Reviews citing this publication (1)
- An Update on JAK Inhibitors. Musumeci F, Greco C, Giacchello I, Fallacara AL, Ibrahim MM, Grossi G, Brullo C, Schenone S. Curr Med Chem 26 1806-1832 (2019)
Articles citing this publication (3)
- Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof. Davis RR, Li B, Yun SY, Chan A, Nareddy P, Gunawan S, Ayaz M, Lawrence HR, Reuther GW, Lawrence NJ, Schönbrunn E. J Med Chem 64 2228-2241 (2021)
- Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2). Liu Q, Batt DG, Lippy JS, Surti N, Tebben AJ, Muckelbauer JK, Chen L, An Y, Chang C, Pokross M, Yang Z, Wang H, Burke JR, Carter PH, Tino JA. Bioorg. Med. Chem. Lett. 25 4265-4269 (2015)
- Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors. Wang T, Liu X, Hao M, Qiao J, Ju C, Xue L, Zhang C. Bioorg. Med. Chem. Lett. 26 2936-2941 (2016)